ResearcherUniversity of Cape TownActive in the last 2 years

Karabo Serala

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0925-1108; OpenAlex author ID A5081037650. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2024: 1 paper · 2025: 1 paper

Papers 2

The T-Box Transcription Factors TBX2 and TBX3 Are Molecular Targets of Piroctone Olamine in the Treatment of Pancreatic Cancer. Co-author DOI 10.1111/jcmm.70736 ↗
Pyrvinium Pamoate Alone and With Gemcitabine Exhibits Anti-Pancreatic Cancer Activity in 2D and 3D Cell Culture Models. Co-author DOI 10.1111/jcmm.70222 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Sharon Prince · 2 shared papers, 2024–2025 · strength 0.63
- Paper Pyrvinium Pamoate Alone and With Gemcitabine Exhibits Anti-Pancreatic Cancer Activity in 2D and 3D Cell Culture Models. DOI 10.1111/jcmm.70222 ↗
- Paper The T-Box Transcription Factors TBX2 and TBX3 Are Molecular Targets of Piroctone Olamine in the Treatment of Pancreatic… DOI 10.1111/jcmm.70736 ↗
Odile Gayet · 1 shared paper, 2025 · strength 0.27
- Paper The T-Box Transcription Factors TBX2 and TBX3 Are Molecular Targets of Piroctone Olamine in the Treatment of Pancreatic… DOI 10.1111/jcmm.70736 ↗
Nelson Dusetti · 1 shared paper, 2025 · strength 0.27
- Paper The T-Box Transcription Factors TBX2 and TBX3 Are Molecular Targets of Piroctone Olamine in the Treatment of Pancreatic… DOI 10.1111/jcmm.70736 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.